Leonabio Inc

This proposal asks shareholders to approve issuance of 5,502,402 shares upon exercise of a pre-funded warrant previously issued to Sermonix as partial consideration for a license to develop lasofoxifene. The exercise is precluded by Nasdaq Rule 5635(a)(2) until shareholder approval because the transaction involved a party (Sermonix) tied to an entity (an affiliate of Perceptive) that had a significant interest, creating a potential 5%+ change in ownership or voting power. Management is pursuing approval to remove the exercise restriction so the company can complete the economic terms of the license and allow Sermonix to convert the warrant into common stock, increasing liquidity and aligning consideration with the license grant. The filing discloses that if approval is not obtained, the warrant will remain non-exercisable and Sermonix has a contractual redemption right that could force the company to pay up to approximately $7.5 million over time, creating potential cash outflows and transaction uncertainty. The board emphasizes Nasdaq compliance and notes the connection between Sermonix and Perceptive (a Perceptive affiliate held ~29% of Sermonix and a board member has ties to Perceptive), which heightens the need for a stockholder vote under Nasdaq rules. Approving the proposal would enable potential dilution to current holders but would complete a strategic license that transfers rights and obligations for Phase 3 development and commercialization of lasofoxifene outside certain territories. The board unanimously recommends a FOR vote, citing regulatory compliance, completion of the negotiated transaction, and avoidance of the potential redemption payments and repeated votes. Key risk factors for analysts include dilution magnitude, the related‑party aspect (Perceptive connection), and the contractual redemption exposure if approval is delayed or withheld. Overall, the proposal is transactional and regulatory in nature: it is intended to effectuate the license consideration as negotiated while managing Nasdaq listing requirements and the company’s cash exposure if approval is not obtained.

This proposal seeks shareholder approval under Nasdaq Rule 5635(b) to authorize Sermonix to exercise its pre‑funded warrant even if such exercise would result in Sermonix and aggregated parties owning more than 19.99% of LeonaBio’s outstanding common stock. Nasdaq Rule 5635(b) treats issuances that could effect a change of control—commonly defined at or above 20% ownership—as requiring shareholder approval; management is therefore asking shareholders to remove the 19.99% exercise cap that otherwise limits Sermonix’s ability to convert its warrant. The company states that absent approval, Sermonix could not exercise to exceed 19.99% and may have redemption rights that could compel the company to pay up to about $7.5 million if approvals are delayed—representing material contingent cash exposure. The context includes a related-party overlay: an affiliate of Perceptive held approximately 29% of Sermonix at signing and a board member has ties to Perceptive, which increases scrutiny under Nasdaq related-party guidance. Approval would permit potential concentrated ownership by Sermonix, which could influence corporate governance and voting outcomes; it would also finalize the negotiated economic arrangement of the license transaction. The Board recommends FOR, framing the vote as necessary to comply with Nasdaq and to implement the commercial terms of the license, while also noting the dilution and governance concentration risks. Analysts should weigh the strategic benefits from the lasofoxifene license and transfer of development responsibilities against the governance implications of a large new holder and the contingent redemption exposure if stockholder approval is not timely obtained.

This proposal requests shareholder approval under Nasdaq Rule 5635(b) to allow Perceptive (and its affiliates) to exercise PIPE Pre‑Funded Warrants and other PIPE warrants even if such exercises would result in Perceptive owning more than 19.99% of the company's shares. The underlying PIPE Financing raised approximately $90 million in gross proceeds and included substantial securities (shares, pre-funded warrants, and accompanying warrants); Perceptive purchased about $20 million of the securities. The company discloses that, assuming full theoretical exercise, Perceptive could hold a pro forma majority stake (illustratively up to ~64% in an extreme full-exercise scenario), though many warrants are not yet exercisable or are cashless/net exercise instruments and exercise limitations and voting restrictions apply (notably Perceptive agreed not to vote 1,319,026 shares on Proposal 3). Management seeks to remove the 19.99% cap so that contractual exercise rights function as negotiated and to ensure compliance with Nasdaq listing rules. The Board recommends FOR, emphasizing the necessity to implement the PIPE financing’s economic terms and Nasdaq compliance; however, the proposal raises governance and control concentration risks that analysts should evaluate, including potential future influence by Perceptive, dilution to existing shareholders, and the limited immediate exercisability of some warrants which moderates short‑term impact. The company also details structural limits (e.g., certain purchasers selected lower ownership caps) and the Voting Restriction which reduces Perceptive’s ability to influence the vote on this specific proposal. For sophisticated analysis, the trade-offs are capital raised and development funding versus potential ownership concentration and related governance effects.

Proposal 4 requests shareholder approval of the LeonaBio 2026 Equity Incentive Plan, which would replace the 2020 plan and reserve an initial 5,700,000 shares (plus up to 1,300,000 shares recycled from the 2020 plan) for awards, with an annual automatic increase each January 1st equal to up to 5% of outstanding shares and pre‑funded warrants through 2036. Management frames the plan as necessary to continue market‑competitive equity grants to attract, retain and motivate executives, employees and consultants, and to align their incentives with long‑term shareholder value. The plan authorizes a broad range of award types (incentive and nonstatutory options, RSUs, SARs, performance awards), includes administration by an independent compensation committee, director annual compensation caps, transfer restrictions, clawback provisions and standard change‑in‑control and adjustment protections. Approval would increase potential future dilution; management quantifies prior grants and provides examples of recent awards and the requested share reserve, and emphasizes that available shares under current plans would otherwise be insufficient to meet anticipated grant needs. From a governance perspective the plan includes standard protections (administrator discretion limits, Section 409A compliance, limits on director compensation) but also provides broad administrator authority (including exchange programs and adjustments), so analysts should monitor future administrator actions and potential dilution pacing. The Board unanimously recommends FOR, asserting that the plan is consistent with best practices and necessary to support growth and retention during advancement of licensed assets and clinical programs. For evaluation, consider plan runway given automatic increases, potential dilution depending on exercise/settlement mix (cash vs. shares), and the interplay with the proposed increase in authorized shares under Proposal 5.

This proposal asks shareholders to approve an amendment to increase authorized common stock from 90,000,000 to 400,000,000 shares, raising total authorized capital from 190,000,000 to 500,000,000 shares. Management explains the increase is to ensure sufficient unissued shares are available for financings, strategic transactions, equity compensation plans and other corporate actions; it quantifies current reserves and illustrates that only ~20.1 million shares remain unreserved under the current charter (and ~14.4 million if the 2026 Equity Incentive Plan is approved). The board positions this as a routine corporate housekeeping action to preserve flexibility, and notes broker-dealers typically may vote on routine charter amendment matters. However, increasing authorized shares can be dilutive if the board subsequently issues a substantial portion of the newly authorized shares without shareholder approval, and can raise takeover-defense concerns depending on timing and intent. The board disclaims any immediate plan to issue all new shares but acknowledges the possibility; approval would give the board significant issuance capacity. The Board unanimously recommends FOR, citing the need to maintain operational flexibility as clinical and licensing activities proceed and to support the contemplated equity incentive plan and other financing needs. Analysts should consider the balance between preserving financing flexibility and the potential for future dilution or governance changes if large issuances occur without further shareholder votes.

Proposal 6 requests authority to adjourn the Special Meeting, if the board deems necessary, to permit additional time to solicit proxies in the event there are insufficient votes to approve any of Proposals 1–5. Management explains that approval would allow designated proxy holders to adjourn and reconvene the meeting without additional notice (within certain limits) to solicit further support, effectively providing the board procedural flexibility to seek a favorable result on contested items. While procedurally common, the adjournment authority has strategic implications: the company could, as disclosed, adjourn even when a proposal initially appears likely to fail and continue to solicit votes, which may pressure dissident voters or extend the solicitation timeline. The board recommends FOR, framing the measure as a routine procedural authorization to ensure the meeting can be continued if necessary to secure adequate votes, avoid the cost and delay of calling a separate meeting, and implement negotiated transactions. For analysts, the vote is largely administrative but bears on how aggressively management might pursue additional solicitation post-meeting; it also intersects with the disclosed redemption and re-vote obligations tied to the Sermonix and PIPE transactions if approvals are not timely obtained. The governance trade-off is between efficient implementation of board-supported transactions and the shareholder interest in finality and preventing protracted solicitation that could change initial outcomes.